.
From slide 17 of the April investor presentation … the “Development Roadmap” …
We can expect that several new products will transition from design / development out into the world of regulatory clearance and user evaluation in the next few months
And 1st quarter of next year
- in the case of CardioCel 3D Stage 1 Arch moving to commercialization
- half pipe conduit
- Adult AV leaflets
And whatever it is
- Pediatric leaflets
- Adapt Jugular Vein (no valve)
So I think we will be receiving lots of good news updates as all this new product development stream starts to see the light of day
- Samurai (various) is coming along from Q4 -2018
Hopefully it will add to the financials to add a positive tone
.
. From slide 17 of the April investor presentation … the...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |